Evan J Lipson
JHU Sidney Kimmel Comprehensive Cancer Center LAO · Johns Hopkins University · The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Evan J Lipson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:42 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05896839 · Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerNational Cancer Institute (NCI) · recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 · principal investigator
- Ph1NCT03816332 · Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersNational Cancer Institute (NCI) · active not recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 · principal investigator
- Ph2NCT03521830 · Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Basal Cell Carcinoma · principal investigator
- Ph3NCT02427893 · Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant MelanomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · withdrawn · Melanoma · principal investigator
- Ph1NCT01435499 · Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected MelanomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2014 to 2026Named on NCT05896839, NCT03816332
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:42 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol · 20141,889 citationsRCR 53.5
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med · 20221,652 citationsRCR 113.5
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.N Engl J Med · 20161,007 citationsRCR 30.3
- Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.Clin Cancer Res · 2013438 citationsRCR 10.9
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.J Clin Oncol · 2019310 citationsRCR 10.5
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.N Engl J Med · 2022290 citationsRCR 20.0
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.J Nucl Med · 2017188 citationsRCR 5.9
- 127 citationsRCR 9.5
- Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.J Immunother Cancer · 2021124 citationsRCR 7.0
- Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.J Immunother Cancer · 2017109 citationsRCR 3.8